Research Papers:
eIF3i activity is critical for endothelial cells in tumor induced angiogenesis through regulating VEGFR and ERK translation
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2170 views | HTML 3159 views | ?
Abstract
Yaguang Zhang1,*, Ping Wang1,*, Qian Zhang1, Xiaomin Yao1, Linjie Zhao1, Yibin Liu1, Xiaowei Liu1, Rui Tao1, Chuan Yu1, Yuhao Li2, Xiangrong Song1, Shaohua Yao1
1State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
2Key Laboratory of Tumor Microenvironment and Neurovascular Regulation, Nankai University School of Medicine, Tianjin, China
*These authors have contributed equally to this work
Correspondence to:
Shaohua Yao, email: [email protected]
Xiangrong Song, email: [email protected]
Keywords: eIF3i, selective translational control, tumor angiogenesis, VEGFR, ERK
Received: May 11, 2016 Accepted: November 30, 2016 Published: February 11, 2017
ABSTRACT
Translational control is a critical step in the regulation of gene expression. Accumulating evidence shows that translational control of a subgroup of mRNAs tends to be selective. However, our understanding of the function of selective translational control in endothelial cells is still incomplete. We found that a key translational regulator, eIF3i, is highly expressed in endothelial cells during embryonic and tumor angiogenesis. Knockdown of eIF3i restrained cell proliferation and migration in endothelial cells. In zebrafish angiogenesis model, eIF3i mutant endothelial cells could not respond to induction signals from tumor mass. Mechanistically, we showed that eIF3i knockdown reduced VEGFR/ERK signaling by down-regulating VEGFR2 and ERK protein expression. Gene therapy model suggested that the growth and metastasis of cancer cells were suppressed by eIF3i shRNA. Therefore, our work established a selective translational regulatory mechanism during tumor induced angiogenesis and suggested that targeting eIF3i may be applicable for anticancer therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15274